Objective To analyze the effects of bevacizumab on major pathological response(MPR)rate and laboratory indices in patients with advanced colorectal cancer(CRC).Methods Seventy-four cases of advanced CRC were admitted to the First Hospital of Zhangjiakou from January 2021 to October 2022 were recruited by convenience sampling method,and they were randomly divided into control group(n=37,receiving chemotherapy)and observation group(n=37,receiving chemotherapy+bevacizumab).The therapeutic effects,serum factors,tumor markers and safety of the two groups were compared.Results After treatment,the MPR rate and objective remission rate(ORR)in the observation group were significantly higher than those of control group(54.05％vs 27.03％,56.76％vs 32.43％,P＜0.05).The serum levels of matrix metalloproteinase 2(MMP2),matrix metalloproteinase 9(MMP9)and vascular endothelial growth factor(VEGF)in the observation group were significantly lower than the control group(P＜0.05).The expression of serum cancer antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate antigen 19-9(CA19-9)in the observation group were significantly lower than the control group(P＜0.05).The incidence of toxic side effects in the observation group was significantly lower than that in the control group(18.92％vs 40.54％,P＜0.05).Conclusion Bevacizumab can achieve significant results in the treatment of advanced CRC.It not only improve the therapeutic effect,improve serum factors,tumor markers,but also promote the effective improvement of the safety of patients.
维普
万方数据